Edna Foa, who died at 88, transformed PTSD treatment by developing prolonged exposure (PE) therapy, which systematically guides patients to confront trauma memories and avoided situations. The New York Times obituary captures her personal journey and clinical breakthroughs but misses the larger pattern: how her work established a rigorous, replicable evidence base at a time when mental health systems face unprecedented demand from post-COVID trauma, conflict zones, and societal violence.

Foa's emotional processing theory posited that PTSD persists because fear structures remain unintegrated; repeated, safe exposure allows new learning to compete with old associations. This was not mere intuition. A landmark 2005 RCT by Foa et al. (Journal of Consulting and Clinical Psychology, n=171 female assault survivors, no industry conflicts) showed PE produced large symptom reductions (effect size ~1.4) with 53% of participants losing their PTSD diagnosis at post-treatment, significantly outperforming waitlist and peer counseling controls. These findings have been replicated and extended in subsequent high-quality RCTs, including veteran and first-responder cohorts.

Synthesizing this with Cusack et al.'s 2016 Cochrane systematic review (43 studies, moderate-to-high quality evidence, total N>4,000) and a 2023 network meta-analysis in The Lancet Psychiatry (analyzing 77 RCTs across psychotherapies and pharmacotherapies), a clear hierarchy emerges: trauma-focused therapies like PE and cognitive processing therapy consistently rank highest for sustained remission. Notably, PE showed comparable outcomes to EMDR but with a clearer mechanistic explanation and lower training burden in scaled VA rollouts. What original coverage often gets wrong is portraying exposure as universally 'harsh'; dropout rates in observational implementation studies hover at 25-35%, yet completers show durable gains at 12-month follow-up, and dropout can be mitigated with cultural adaptations and motivational enhancement—factors rarely discussed in mainstream obituaries.

Foa's approach stands in contrast to less evidence-based practices that proliferated during the pandemic mental health surge. Pharmaceutical industry influence remains minimal in her body of work, unlike antidepressant trials for PTSD that frequently show smaller effect sizes and higher relapse. Her passing arrives as global PTSD prevalence climbs: WHO modeling post-2022 estimates hundreds of millions affected by war, displacement, and collective trauma. The missed connection is implementation science—despite APA and VA clinical practice guidelines endorsing PE at the highest level, fewer than 20% of eligible patients receive it due to therapist shortages and reimbursement models favoring short-term medication management.

Foa's legacy therefore demands more than remembrance. It calls for investment in training pipelines, digital adaptations of PE, and equity-focused research examining how exposure protocols perform in non-Western and marginalized communities (currently underrepresented in the RCT literature). In an age of mental health crises, her evidence-first orientation remains the clearest path forward: name the fear, engage it safely, and let the brain rewrite its own story.